{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:38:58Z","timestamp":1779367138882,"version":"3.53.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T00:00:00Z","timestamp":1630195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004382","name":"Polska Akademia Nauk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejphar.2021.174460","type":"journal-article","created":{"date-parts":[[2021,8,29]],"date-time":"2021-08-29T09:29:28Z","timestamp":1630229368000},"page":"174460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease"],"prefix":"10.1016","volume":"910","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-6511","authenticated-orcid":false,"given":"Tomasz","family":"Lenda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Ossowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemencja","family":"Berghauzen-Maciejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Mat\u0142oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Pieczykolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-1620","authenticated-orcid":false,"given":"Jolanta","family":"Konieczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174460_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbr.2007.01.028","article-title":"Repetitive vibrissae-elicited forelimb placing before and immediately after unilateral 6-hydroxydopamine improves outcome in a model of Parkinson's disease","volume":"179","author":"Anstrom","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s43440-020-00060-y","article-title":"Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats","volume":"72","author":"Arakawa","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2021.174460_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.27341","article-title":"A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys","volume":"33","author":"Beck","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2021.174460_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bov\u00e9","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2021.174460_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1460-9568.2005.03944.x","article-title":"Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment","volume":"21","author":"Carta","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2021.174460_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jama.1975.03240200043025","article-title":"Antagonism of levodopa by papaverine","volume":"231","author":"Duvoisin","year":"1975","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2021.174460_bib9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.ejphar.2021.174460_bib10","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","article-title":"Current approaches to the treatment of Parkinson's disease","volume":"27","author":"Ellis","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2021.174460_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuroscience.2015.04.027","article-title":"Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson\u2019s disease","volume":"298","author":"Fidalgo","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2021.174460_bib12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and Movement Disorder Society Evidence-based Medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2021.174460_bib13","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.euroneuro.2019.12.006","article-title":"The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of Parkinson's disease","volume":"31","author":"Gajos-Draus","year":"2020","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2021.174460_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuropharm.2015.05.024","article-title":"The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents","volume":"99","author":"Gentzel","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2021.174460_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","article-title":"Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms","volume":"28","author":"Giorgi","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2011.04.006","article-title":"PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology","volume":"43","author":"Giorgi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2021.174460_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0091-3057(87)90490-4","article-title":"Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response","volume":"27","author":"Hillegaart","year":"1987","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2021.174460_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pharep.2017.05.016","article-title":"Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle","volume":"69","author":"Kami\u0144ska","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2021.174460_bib20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11481-020-09943-6","article-title":"The potent PDE10A inhibitor MP-10 (PF-2545920) suppresses microglial activation in LPS-induced neuroinflammation and MPTP-induced Parkinson's disease mouse models","volume":"16","author":"Kim","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174460_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2013.12.019","article-title":"Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra","volume":"261","author":"Konieczny","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbr.2015.01.043","article-title":"Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA","volume":"283","author":"Konieczny","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib23","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jnr.24022","article-title":"Combined ipsilateral limb use score as an index of motor deficits and neurorestoration in parkinsonian rats","volume":"95","author":"Leikas","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuropharm.2013.08.010","article-title":"Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions","volume":"76","author":"Mango","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.57","article-title":"PDE10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways","volume":"2","author":"Megens","year":"2014","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejphar.2021.174460_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2018.05.043","article-title":"Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines","volume":"155","author":"Moszczynski Petkowski","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2021.174460_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neures.2017.06.007","article-title":"The phosphodiesterase 10A selective inhibitor, TAK-063, induces c-Fos expression in both direct and indirect pathway medium spiny neurons and sub-regions of the medial prefrontal cortex in rats","volume":"125","author":"Nakatani","year":"2017","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib29","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/brain\/awv219","article-title":"Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2021.174460_bib30","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib31","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib32","first-page":"257","article-title":"Regulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition: implications for the treatment of Parkinson's disease","volume":"vol. 17","author":"Padovan-Neto","year":"2017"},{"key":"10.1016\/j.ejphar.2021.174460_bib33","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.ejphar.2021.174460_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.neuropharm.2009.11.012","article-title":"A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug","volume":"58","author":"Pinna","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib35","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0060-15.2015","article-title":"Selective effects of PDE10A inhibitors on striatopallidal neurons require phosphatase inhibition by DARPP-32","volume":"2","author":"Polito","year":"2015","journal-title":"eNeuro"},{"key":"10.1016\/j.ejphar.2021.174460_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1460-9568.2004.03566.x","article-title":"Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation","volume":"20","author":"Sancesario","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2021.174460_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neuint.2014.10.004","article-title":"Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?","volume":"79","author":"Sancesario","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2021.174460_bib38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib39","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174460_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2021.174460_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuropharm.2009.09.008","article-title":"Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase","volume":"58","author":"Strick","year":"2010","journal-title":"PDE10A. Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib45","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of Phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174460_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2014.01.042","article-title":"Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"265","author":"Tronci","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2021.174460_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuropharm.2013.10.015","article-title":"Phosphodiesterase 10A Inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications","volume":"77","author":"Uthayathas","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuropharm.2015.08.008","article-title":"Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum","volume":"99","author":"Wilson","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2021.174460_bib50","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.expneurol.2004.09.005","article-title":"Testing forelimb placing \u201eacross the midline\u201d reveals distinct, lesion-dependent patterns of recovery in rats","volume":"191","author":"Woodlee","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2021.174460_bib51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:17:04Z","timestamp":1762143424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":51,"alternative-id":["S0014299921006142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174460","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174460"}}